The Prognostic Significance of APOBEC3B and PD-L1/PD-1 in Nasopharyngeal Carcinoma

Autor: Changyin Feng, Benhua Xu, QiaoLing Zheng, Yinghong Yang, Jian-ping Huang, YingYing Zhang
Rok vydání: 2020
Předmět:
Adult
Male
0301 basic medicine
Oncology
medicine.medical_specialty
Histology
Adolescent
Carcinogenesis
Programmed Cell Death 1 Receptor
B7-H1 Antigen
Pathology and Forensic Medicine
Metastasis
Minor Histocompatibility Antigens
Young Adult
03 medical and health sciences
0302 clinical medicine
Cytidine Deaminase
Internal medicine
PD-L1
otorhinolaryngologic diseases
medicine
Humans
Clinical significance
In patient
Neoplasm Metastasis
Stage (cooking)
Aged
Neoplasm Staging
Nasopharyngeal Carcinoma
biology
business.industry
Significant difference
Nasopharyngeal Neoplasms
Middle Aged
Prognosis
medicine.disease
stomatognathic diseases
Medical Laboratory Technology
030104 developmental biology
Nasopharyngeal carcinoma
030220 oncology & carcinogenesis
biology.protein
Immunohistochemistry
Female
Neoplasm Recurrence
Local
business
Zdroj: Applied Immunohistochemistry & Molecular Morphology.
ISSN: 1541-2016
DOI: 10.1097/pai.0000000000000852
Popis: Purpose Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3B (APOBEC3B) is a recently discovered protein that is considered important in causing mutations in tumor cell genome bases. Whether APOBEC3B is expressed in nasopharyngeal carcinoma (NPC) still remains unknown. Studies have shown that programmed-cell-death receptor-1 ligand (PD-L1) is highly expressed in NPC, but its clinical significance has not been fully elucidated. We aimed to evaluate APOBEC3B and PD-L1 protein expression in NPC and also investigate their prognostic significance. Materials and methods One hundred and three patients with NPC were retrospectively collected in this study, and were followed-up for 5 years. The expression of APOBEC3B and PD-L1/PD-1 in NPC was detected by immunohistochemical staining. Results High expression of APOBEC3B was observed in 42.7% of NPC patients. The high expression rate of APOBEC3B was 31.5% in patients without recurrence or metastasis within 5 years, and 55.1% in those patients with recurrence or metastasis, and the difference was statistically significant (P=0.016). There was no significant difference in APOBEC3B expression among patients with different sex, age group, and clinical stage (P>0.05). The positive expression rate of PD-L1 was 55.3% in all patients with NPC. There was no significant difference in PD-L1 expression among patients with different sex, age group, clinical stage, and tumor recurrence or metastasis condition (P> 0.05). There was no significant correlation between the expression of APOBEC3B and PD-L1 in NPC patients. The positive expression rate of PD-1 was 1.9% (2/103) in patients with NPC. Conclusions APOBEC3B showed association with aggressive behavior and poor outcome in NPC, and is also considered as a potential marker for predicting NPC recurrence or metastasis. PD-L1 is not associated with the aggressive behavior and poor outcome in NPC.
Databáze: OpenAIRE
Externí odkaz: